drugset / Trial / NCT04338581
Evaluation of AMG 714 for Vitiligo
Phase 2
Completed
60 enrolled
National Institute of Allergy and Infectious Diseases (NIAID)
Amgen · collabImmune Tolerance Network (ITN) · collabPPD Development, LP · collabRho Federal Systems Division, Inc. · collab
RandomizedParallel-groupQuadruple-blindTreatment
Summary
This study is designed to evaluate the efficacy of AMG 714 for the treatment of adult participants with vitiligo.
Timeline
- Start
- 2020-12-11
- Primary completion
- 2024-10-16
- Completion
- 2025-04-02
Outcome
Missed primary endpoint
registry analysis (superiority test); AMG 714 vs Placebo; p = 0.411; Fisher Exact NCT04338581 ↗
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | ORDESEKIMAB | Monoclonal antibody | 300 mg | Subcutaneous |